Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, MD
Published Online: Monday, June 9, 2014


Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
Online CME Activities
Free CME from PER
Evaluating the Neoadjuvant Treatment of Breast Cancer
Cardiology Review/CME Reviews: Volume 31, Number 2
Community Practice Connections: 19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
Addressing Disparities in Care Specific to Patients With Lung Cancer: Health Literacy
More Reading
$auto_registration$